RecruitingMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Eligible age
18+ yrs
Accepts
Men
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or recurrent Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
Sponsor: Novartis Pharmaceuticals
Where it's recruiting
Alabama
Birmingham
Iowa
Iowa City
Kansas
Westwood · Wichita
North Carolina
Durham
South Carolina
Charleston · Myrtle Beach
Utah
Salt Lake City
Source: ClinicalTrials.gov · NCT07190300 · last updated 2026-06-23